Effect of Smart Watch and App on PAP Adherence in OSA (Watch-OSA)

Last updated: April 16, 2024
Sponsor: Seoul National University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sleep Apnea Syndromes

Treatment

the smart watch and Samsung Health app

Clinical Study ID

NCT05530265
22070571340
  • Ages 22-75
  • All Genders

Study Summary

Continuous positive airway pressure (CPAP) is highly effective in treating obstructive sleep apnea (OSA). However, this treatment modality relies heavily on patient adherence, and poor adherence to the treatment limits its effectiveness in treating OSA. Strategies to augment adherence are needed in the management of OSA.

The smart watch and linked app provide various health information, including sleep, snoring or oxygen saturation during sleep, exercise, blood pressure, and electrocardiogram. The smart watch and linked app could potentially improve adherence to positive airway pressure (PAP) treatment.

This randomized controlled trial (RCT) aimed to examine whether the use of smart watch and app can increase PAP adherence in patients with OSA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • diagnosed with OSA (apnea-hyponea index [AHI])≥ 5 /h) by type 1 polysomnography
  • no prior use of PAP (CPAP or auto-adjusting PAP [APAP]), or no prior use of PAP withinthe previous 90 days in patients who had received PAP therapy, or current PAP userswith average daily usage (all days) < 4 hours within the previous 90 days

Exclusion

Exclusion Criteria:

  • patients who refuse PAP therapy
  • patients who have used a smart watch (e.g., Galaxy Watch, Apple Watch, etc.) withinthe previous 90 days
  • patients with central sleep apnea or neuromuscular disease
  • patients receiving supplemental oxygen therapy due to underlying diseases includingheart failure, stroke, chronic obstructive pulmonary disease, interstitial pulmonarydisease, hypoventilation syndrome, or whose baseline oxygen saturation is less than 90%
  • patients with implanted cardiac pacemakers, defibrillators, or other electronicdevices
  • patients who are inexperienced in using smartphones, apps, or smart watches
  • patients with an inability or unwillingness to provide informed consent

Study Design

Total Participants: 92
Treatment Group(s): 1
Primary Treatment: the smart watch and Samsung Health app
Phase:
Study Start date:
August 22, 2022
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Seoul National University Hospital

    Seoul, 03080
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.